Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibopamine SCHEMBL3144094 | 1.00 | ADRB2 (1.00) | ADRB2DRD1ADRA2ADRD2ADRA2C | |
| Ibopamine SCHEMBL32682197 | 1.00 | ADRB2 (1.00) | ADRB2DRD1ADRA2ADRD2ADRA2C | |
| Ibopamine SCHEMBL1412013 | 0.99 | ADRB2 (0.97) | ADRB2DRD1ADRA2ADRD2ADRA2C | |
| SCHEMBL23676962 | 0.93 | ADRB2 (0.87) | ADRB2DRD1ADRA2ADRD2ADRA2C | |
| Ibopamine SCHEMBL1411634 | 0.92 | ADRB2 (0.85) | ADRB2DRD1ADRA2ADRD2ADRA2C | |
| Ibopamine SCHEMBL1411632 | 0.92 | ADRB2 (0.85) | ADRB2DRD1ADRA2ADRD2ADRA2C | |
| Hydrochloric Acid SCHEMBL9346052 | 0.92 | ADRB2 (0.85) | ADRB2DRD1ADRA2ADRD2ADRA2C | |
| Hydrochloric Acid SCHEMBL9344074 | 0.89 | ADRB2 (0.79) | ADRB2DRD1ADRA2ADRD2ADRA2C | |
| SCHEMBL10438186 | 0.89 | ADRB2 (0.79) | ADRB2DRD1ADRA2ADRD2ADRA2C | |
| Hydrochloric Acid SCHEMBL9346080 | 0.88 | ADRB2 (0.77) | ADRB2DRD1ADRA2ADRD2ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1851 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS, INC. | 2026-01-29 | — | — | US | claimed |
| CN-119698288-A | Treatment of autoimmune diseases with insulin-like growth factor 1 receptor ligands conjugated to agents | 利鲁姆治疗公司 | 2025-03-25 | — | — | CN | claimed |
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| US-20240139224-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | AMERICAN ENTERTAINMENT PROPERTIES CORP., AS LENDER | 2024-05-02 | — | — | US | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| EP-3852608-A1 | COMPOSITIONS AND METHODS FOR GLAUCOMA | Aufbau Medical Innovations Limited (IE) | 2021-07-28 | — | — | EP | claimed |
| US-20210161932-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS LLC | 2021-06-03 | — | — | US | claimed |
| CN-111317736-B | Application of quinoline alkaloid in preparation of medicine for treating atherosclerosis | 济南大学 | 2021-01-29 | — | — | CN | claimed |
| CN-111317736-A | Application of quinoline alkaloid in preparation of medicine for treating atherosclerosis | 济南大学 | 2020-06-23 | — | — | CN | claimed |
| EP-0509598-A1 | Use of ibopamine for the manufacture of a pharmaceutical composition for the treatment of glaucomatous optic neuropathy | ZAMBON GROUP S.p.A. (IT) | 1992-10-21 | — | — | EP | claimed |
| EP-0442958-A1 | PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC USE COMPRISING A WATER SOLUBLE ACID ADDITION SALT OF IBOPAMINE. | ZAMBON SPA (IT) | 1991-08-28 | — | — | EP | claimed |
| WO-1990004964-A1 | PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC USE COMPRISING A WATER SOLUBLE ACID ADDITION SALT OF IBOPAMINE | ZAMBON GROUP S.P.A. (IT) | 1990-05-17 | — | — | WO | claimed |
| EP-0351017-A2 | Pharmaceutical composition useful for the treatment of cardiovascular diseases | ZAMBON GROUP S.p.A. (IT) | 1990-01-17 | — | — | EP | claimed |
| EP-0205606-B1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS MYDRIATICS | SIMES, SOCIETA ITALIANA MEDICINALI E SINTETICI, S.P.A. (IT) | 1989-09-06 | — | — | EP | claimed |
| EP-0129383-B1 | PROCESS FOR THE PREPARATION OF 3,4-DI-ISOBUTYRYLOXY-N-METHYL-PHENETHYLAMINE | Farmos-Yhtyma Oy (FI) | 1988-12-28 | — | — | EP | claimed |
| US-4764530-A | IBOPAMINE | AZIENDE CIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1988-08-16 | — | — | US | claimed |
| EP-0205606-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS MYDRIATICS. | SIMES (IT) | 1986-12-30 | — | — | EP | claimed |
| WO-1986003970-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS MYDRIATICS | SIMES, SOCIETÀ ITALIANA MEDICINALI E SINTETICI, S. (IT) | 1986-07-17 | — | — | WO | claimed |
| EP-0129383-A1 | Process for the preparation of 3,4-di-isobutyryloxy-N-methyl-phenethylamine | Farmos-Yhtyma Oy (FI) | 1984-12-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | CYP21A2, HSD11B2, CA2 | ADRB2 229/4885DRD1 1707/4885ADRA2A 599/4885 |
| US-20210161932-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | CA4, CA9, CA7 | ADRB2 543/4885DRD1 4387/4885ADRA2A 547/4885 |
| US-20240139224-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | CA4, CA9, CA7 | ADRB2 543/4885DRD1 4387/4885ADRA2A 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.